The invention relates to triesters of cyclohexanetripropionic acid, preparation thereof and use thereof as plasticizers for polymers wherein examples of the triester of cyclohexanetripropionic acid include tri(.sup.nbutyl) cyclohexane-1,2,4-tripropionate, tri(methylpropyl) cyclohexane-1,2,4-tripropionate, tri(.sup.npentyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isopentyl) cyclohexane-1,2,4-tripropionate, tri(2-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(3-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isohexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isoheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.noctyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isooctyl) cyclohexane-1,2,4-tripropionate, tri(2-ethylhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nnonyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isononyl) cyclohexane-1,2,4-tripropionate, tri(.sup.ndecyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isodecyl) cyclohexane-1,2,4-tripropionate, and tri(2-propylheptyl) cyclohexane-1,2,4-tripropionate.

The invention relates to triesters of cyclohexanetripropionic acid, preparation thereof and use thereof as plasticizers for polymers wherein examples of the triester of cyclohexanetripropionic acid include tri(.sup.nbutyl) cyclohexane-1,2,4-tripropionate, tri(methylpropyl) cyclohexane-1,2,4-tripropionate, tri(.sup.npentyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isopentyl) cyclohexane-1,2,4-tripropionate, tri(2-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(3-methylbutyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isohexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isoheptyl) cyclohexane-1,2,4-tripropionate, tri(.sup.noctyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isooctyl) cyclohexane-1,2,4-tripropionate, tri(2-ethylhexyl) cyclohexane-1,2,4-tripropionate, tri(.sup.nnonyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isononyl) cyclohexane-1,2,4-tripropionate, tri(.sup.ndecyl) cyclohexane-1,2,4-tripropionate, tri(.sup.isodecyl) cyclohexane-1,2,4-tripropionate, and tri(2-propylheptyl) cyclohexane-1,2,4-tripropionate.

The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.

The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.

This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.

This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.

Compounds of the formula 1 ##STR00001##
wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2 ##STR00002##

Compounds of the formula 1 ##STR00001##
wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2 ##STR00002##

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of salts of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and psoriasis.

A process of converting a carbon-carbon multiple bond to a cyclopropane ring, comprising the addition of a N-alkyl-N-nitroso compound to a mixture of alkene precursor, aqueous base and Pd(II)-catalyst, with the N-alkyl-N-nitroso compound obtained directly from an alkyl amine derivative, NaNO.sub.2 and an acid via phase separation of the N-alkyl-N-nitroso compound from the aqueous phase.